Insulet Corporation
Insulet Corporation (PODD) manufactures and sells tubeless insulin pump systems for diabetes management, with a dominant political signal being $3.8M in annual doctor payments (2024) and a single congressional trader making two purchases in August 2025.
BusinessWhat PODD does
Insulet Corporation designs, manufactures, and sells the Omnipod System, a tubeless insulin pump for people with insulin-dependent diabetes. Its revenue is primarily derived from the sale of its disposable Pods and associated Dash and Omnipod 5 handheld devices. The company operates in the medical device sector, specifically focused on diabetes care technology.
12 months past · 3 months futurePODD activity timeline
Executive Branch ConflictsPODD held by Trump-administration officials
Lifetime Government AwardsPODD federal contracts by year
Smart Money · 13F HoldingsHedge funds holding PODD
Politicians Trading PODDMembers of Congress with recent PODD positions
Congressional TradesWho in Congress is trading PODD
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills Affecting PODDLive legislation impacting this stock
Political ProfileWhere PODD sits in Washington
[object Object]
STRUCTURAL: High regulatory density (85) due to healthcare sector and $3.8M in annual doctor payments (2024), but zero lobbying spend, zero donations, and no federal contracts. EVIDENTIARY: Single congressional trader (Rep. Khanna) made two purchases in Aug 2025; former President Trump holds two positions (common stock and dividends) per executive_branch_exposure.by_ticker[0].holdings. No corporate insider buys in 180 days. Net: Mixed signals with moderate evidentiary interest offset by lack of structural political engagement.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
Heightened scrutiny of physician payments under Sunshine Act, given $3.8M in annual doctor payments (2024).CMS (Centers for Medicare & Medicaid Services)"get_political_influence.doctor_payments[0].total_payment_usd: 3821252.6 for 2024."
-
Potential legislative changes to Medicare/Medicaid reimbursement for durable medical equipment (DME) and diabetes supplies.Congress, CMS"Recent bill_impacts array shows 8 healthcare bills with estimated revenue impacts ranging from $3.19M to $6.06M."
Regulatory opportunities
-
Potential expansion of coverage for insulin pump systems under federal healthcare programs.CMS"Recent bill_impacts array indicates legislative activity in healthcare sector affecting company revenue."
-
Reduced regulatory barriers for next-generation automated insulin delivery systems.FDA"Inherent for medical device companies in diabetes sector, though no specific RPC field cites FDA activity."
Capitol Hill AlliesChampions & critics
Congressional champions
Congressional critics
- No specific congressional critics identified.
Live signals + predictions for PODD — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades PODD
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord